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Few undertakings have passed through more identi-
fiable steps from laboratory inception to clinical ap-
plication than has liver transplantation. The place-
ment of auxiliary whole livers in dogs was described 
in 1955 by Welch,l and within 5 yr. attempts at total 
host hepatectomy and orthotopic canine liver trans-
plantation (liver replacement in the normal location) 
were successful at both Harvard2 .3 and North-
western University"'; technical problems and the 
features of rejection in untreated animals were de-
lineatedKO~T Under immunosuppression with azathio-
prineB or antilymphocyte serum (ALS) and its globu-
lin derivative (ALG).9 chronic survival was achieved 
after liver replacement in a number of mongrel 
dogs,'-g of which one lived for 11.66 yr.lO 
In pigs. it was soon found that rejection of hepatic 
homografts was relatively mild in comparison with 
that in dogs and that many orthotopic porcine grafts 
supported life for long times. even though immuno-
suppressive treatment was not provided.'·1I-13 Hun-
dreds of experimental studies in various species 
have since been published, clarifying various ques-
tions. filling in innumerable details, and evaluating 
alternative means to prevent rejection. 
The purpose of this article. however. is not to re-
view experimental work. Attention is directed in-
stead to the clinical trials that have been made with 
increasing frequency and success since the first hu-
man transplantation in 1963.14 Orthotopic liver 
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transplantation has seemed to be the most promising 
procedure. but mention is also made in the following 
remarks of provision of an extra liver in an ectopic 
location (auxiliary hepatic transplantation). Aux-
iliary liver transplantation was firs( performed clini-
cally by Absolon et a1. IS 
Orthotopic Transplantation 
Liver replacement on a large scale has been 
carried out in the United States only at the Univer-
sity of Colorado. From March 1963. to December 
1977. we treated 141 patients with liver replacement. 
Follow-ups are available to January 1979. In the 
meanwhile. a major English program was estab-
lished by Caine and Williams, working between the 
University Hospital at Cambridge and King's College 
Hospital in London. '6. '7 Between May 1968. and De-
cember 1977. they treated 74 patients with ortho-
topic liver transplantations and have generously 
supplied to us an unpublished report of these cases 
brought up to May 1978. '6 
The following remarks are based largely on the 
215 cases of the two foregoing series. Other trials 
have been made. of which only a minority have ap-
peared in the literaturel9-31 as case reports or small 
series. The number of unreported cases can be ap-
preciated by the fact that 250 orthotopic liver trans-
plantations had already been recorded 1.5 yr ago in 
the July 1977 issue of the now obsolete Newsletter of 
the Organ Transplantation Registry of the American 
College of Surgeons. Although important. the iso-
lated and sporadic experiences have been hard to 
compile and to follow up accurately for the purposes 
of this review. which are several: (a) to recount the 
early experience with liver replacement; (b) to as-
sess the causes of the overwhelming acute mortality 
in these early cases; (c) to describe the impact of 
( 
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management adjustments upon the subsequent re-
sults; (d) to catalogue the fate of chronic survivors; 
(e) to describe changing or controversial views about 
indications for this operation; (f) to assess the qual-
ity of life in long-term survivors; and (g) to look at 
the prospects for future improvements. 
In reviewing the evolution of the field, results are 
given at the outset, because our opinions about man-
agement, indications for operation, and the need for 
alternative treatment programs have changed 
throughout the years as increasing experience was 
acquired. In England, viewpoints also have shifted 
about several aspects of this complex undertaking. 
The Early Experience 
In Colorado, 111 consecutive patients were 
treated with orthotopic liver transplantation be-
tween March 1963 and July 1976. Of these, only 31 
(28%) survived for as long as 1 yr (Table 1). The rate 
of chronic survival improved only slightly during 
this time. The first 25 recipients, who formed the 
basis of a monograph on liver transplantation,' in-
cluded only five l-yr survivors (20%). The next group 
of 25 contained six (24%), and the group after that 
had eight (32%). There were 12 (33%) l-yr survivors 
among the 36 patients, beginning with OT (ortho-
topic transplant) 76 and ending at OT 111. The sub-
sequent fate of the 31 l-yr survivors from our first 
111 cases is considered below. 
The Cambridge-King's College team headed by 
Caine and Williams also had initially discouraging 
early results. Among their first 35 recipients, there 
were only three l-yr survivors, of whom one lived 
for more than 5 yr. 18 
Reasons for Acute Mortality 
In late 1975 and early 1976, an exhaustive re-
view was undertaken to determine the reasons for 
the high acute mortality at our center. The reasons 
for failure or success in every case were retro-
spectively examined. The central findings32 changed 
our attitudes about the management of subsequent 
cases. 
··e,-···Q ." 
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One expected cause of failure was uncontrolled 
acute rejection. However, acute rejection was the 
primary reason for death in less than 20% of the 
cases. Similarly, chronic rejection, which is typified 
by occlusive arterial disease and parenchymal fibro-
sis of the homograft. accounted for only a few fail-
ures within the 1st yr. 
The main causes of the exorbitant acute mortality 
up to that time were technical or mechanical.32 
These included thrombosis of the homograft blood 
supply, the use of grafts damaged by ischemia, oper-
ative hemorrhage, intraoperative cerebral air embo-
lization originating in the homograft (see below), 
and most importantly, complications from biliary 
duct reconstruction. In the English series, as in our 
own, the role of technical and mechanical problems 
was also recognized.17.18 At the beginning of both the 
Colorado and English series, grafts damaged by 
warm ischemia were used. With acceptance of brain 
death, first in the United States and later in England, 
the specter of transplanting dead organs was almost 
eliminated, because organs could be removed from 
heart-beating cadavers and cooled immediately. 
However, even recently, we have transplanted hope-
lessly damaged organs taken from apparently good 
donors. There is at present no reliable way to pre-
vent such tragedies by any practical test for homo-
graft viability. 
The special problem of biliary reconstruc-
tion. Realization that the biliary tract was the Ach-
illes' heel of liver transplantation prompted major 
reforms both at our center and in England. Until 
1976, we commonly performed cholecystoduodenos-
tomy (Figure lAl. Although the operation was 
simple, obstruction (Figure 2) or bile fistula forma-
tion occurred in 30% of the first 93 patients, almost 
always leading to death. 33•34 Furthermore, homo-
grafts seemingly were subjected to repeated bacte-
rial contamination with resulting cholangitis and 
consequent systemic infection.7.Js.36 If cholecysto-
duodenostomy was the first reconstruction and if a 
secondary operation became necessary, there was a 
high incidence of subsequent duodenal fistula. 34 
Even worse, many of the biliary tract problems were 
not diagnosed until autopsy. 
Table 1. Survival in the Early and Late Phases of the Colorado Experience (Follow-up to January 1979) 
Total Lived> 1 yr 
Series I 
(March 1963-July 1976) 111 a 31 (28%) 
Series 11 
(August 1976-December 1977) 30" 15 (50%) 
a For patients < 18 yr old. the 1-yr survival was 21/61 (34%). For adults. survival was 10/SO (20%). 
b The 17 late deaths were after 1-6 yr. 
C For patients < 18 yr old. the 1-yr survival was 8/13 (62%). For adults, 1-yr suryival was 7/17 (41%). 
d One late death was at 23 mo, and the other at 16.5 mo. 
Alive now 
14 (after 3-9 yr)b 
13 (after 1-2.5 yr)d 
~~a~ ________________________________________________________________ ___ 
r 
----------------____.a 
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Roux 
limb T-tube in reCipient 
common duct 
Figure 1. Techniques of biliary duct reconstruction used for most of the transplantation recipients in the Colorado series. A. Cholecysto-
duodenostomy. This operation is no longer performed. B. Cholecystojejunostomy. C. Choledochojejunostomy after removal of 
gallbladder. D. Choledochocholedochostomy. Note that the T-tube is placed. if possible. in recipient common duct. (By per-
mission of SURGERY. GYNECOLOGY III OBSTETRICS 142:487. 1976.) 
We now believe that the ideal biliary reconstruc-
tion is choledochocholedochostomy using aT-tube 
stent (Figure ID). After operation, the T-tube has 
been left in place as briefly as 1 mo to as long as 2 yr. 
The ability to obtain T-tube cholangiograms post-
operatively as part of the work-up if jaundice reap-
pears has been a great advantage in designing man-
agement. After the T -tube is removed, periodic 
retrograde cholangiography via the duodenum (Fig-
ure 3) is planned for such recipients. 
Choledochocholedochostomy often is not feasible, 
as, for example, in children with biliary atresia. As 
an alternative we perform cholecystojejunostomy 
(Figure IB) or choledochojejunostomy .(Figure IC) to 
a Roux limb of jejunum. The advantage of chole-
cystojejunostomy is that a large caliber anastomosis 
is possible, even using pediatric livers. No stenting 
or drainage is necessary. The disadvantage is that 
obstruction of the cystic duct (Figure 2) has necessi-
tated reoperation and conversion to choledochojeju-
nostomy (Figure IB to C) in almost one-third of the 
cases. In Figure 4 is shown a transhepatic cholangio-
gram of a patient who had undergone conversion 
from cholecystojejunostomy to choledochojejunos-
tomy. In immunosuppressed patients, the initial con-
struction of the Roux limb has carried an intrinsic 
risk in that perforations of the Roux limb itself or 
the jejunojejunostomy below it occurred in 8 pa-
tients among the first 141.31 Seven of the 8 patients 
died from this complication. 
Caine and his associates have advocated a differ-
ent surgical approach.38 With Caine's technique, the 
common duct and gallbladder are connected to-
gether into a common chamber, and a second 
anastomosis of the gallbladder fundus is made to the 
recipient common duct (or sometimes to a Roux 
iSL 7 7 Dr 7 P 7 7 ifi'S 77 " ?mJ :~ •. , 
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Figure 2. Transhepatic cholangiogram 4 yr after liver transplantation for alcoholic cirrhosis (OT 82). Cholecystoduodenostomy was 
used for biliary drainage. The obstruction was at the cystic duct. which cannot be seen well. The intrahepatic ducts are almost 
normal. but there is a definite dilatation of the common duct including the blind sac distal to the cystic duct entrance (arrow). 
The patient presented with fever. jaundice. and gram negative bacteremia. The diagnosis was cholangitis. Cholecystoduode· 
nostomy was converted to Raux-Y choledochojejunostamy. 
limb).JI\ The cholecystocholedochostomy is stented 
with aT-tube, enabling the biliary system to be fre-
quently studied or irrigated. The English workers 
have been satisfied with this procedure and with it 
biliary tract complications have been reduced.'8 Be-
cause the same thing has been accomplished in our 
later series using more conventional procedures, ex-
perience alone will tell if Caine's somewhat more 
complicated reconstruction is necessary or desir-
able. 
Other technical improvements. By 1976, 
other refinements besides standardization of biliary 
tract reconstruction had been instituted. Frequent 
use was made of microsurgical techniques for vascu-
lar and sometimes for biliary duct anastomoses. This 
was particularly important in children. Methods that 
permitted longer storage were developed in the labo-
ratory and clinical trials were started. The Cam-
bridge-King's College team has used a plasma solu-
tion for cold infusion of the homografts,39.40 and we 
have employed an electrolyte (Collins) solution with 
a composition similar to that found in cells." In 
dogs, the two approaches yield comparable results" 
and permit safe preservation for up to 12 hr. The 
same applies in humans and has permitted the ship-
ment of livers from city to city. McMaster et al.'" 
have cautioned that ischemia and/or bile left within 
the ducts may cause autolysis and set the stage for 
delayed mucosal sloughing and cast formation. It 
has been clear for a long time that thorough washing 
p 
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Figure 3. Transduodenal cholangiogram in an alcoholic patient (OT 102) who received a liver 2 yr ago with choledochocholedochos-
tomy. The T-tube was left in for 1 yr, and the cholangiogram was obtained 6 mo after its removal. 
of the biliary tree is necessary at the time of organ rebral cortex and basal ganglia in 5 patients, central 
removal from the donor! pontine myelinolysis in 5 (often more extensive than 
In patients with cirrhosis and end-stage liver dis- usually reported with liver disease), Wernicke's en-
ease, the combination of portal venous hypertension cephalopathy in 3, glial nodules in 2, and fungal ab-
plus coagulation deficiencies can create a surgical scesses in 1. Alzheimer II astrocytosis was found in 
nightmare. Techniques to reduce the blood loss have all brains available for retrospective study. Most of 
been described.32 At times, devascularization of the the foregoing abnormalities were clearly associated 
native liver and its emergency removal offer the only with preexisting liver disease. It ultimately was real-
chance of survival. Once a well-functioning graft is ized, however. that air emboli from the homografts 
in place. portal hypertension is immediately alle- were responsible for some if not all of the focal in-
via ted and normal clotting slowly develops. In spite farctions. The ease with which air passed to the sys-
of extensive experience. however, the loss of as temic circulation was explicable by the right to left 
much as 50 units of blood still occasionally occurs. venous-arterial shunts that are common in chronic 
Air embolus. Neurologic invalidism was seen liver disease. Air released into the pulmonary circu-
in 9 of the first 48 adult patients who underwent lation apparently passed through these collaterals to 
liver replacement. The complications occurred dur- the systemic circulation, including the arterial sup-
ing or shortly after operation. Several of these pa- ply to the brain. 
tients awakened from anesthesia but then had a sec- With the delineation of this cause for the neuro-
ondary decrease in consciousness. seizures. and logic complications. preventive measures were insti-
other crippling abnormalities. At autopsy. from a tuted.42 During revascularization of the liver. elec-
rew days 10 2 rno lale,.u neuwpalhologic abnonna!· I'olyle solution was slowly infused Ihrough • portal I. j 
ities con_S_is_t_e_d_O_f_m_ul_ti_fo_c_a_l_a_r_e_a_S_O_f_l_'n_f_a_r_ct_i_O_D_i_D_c_e_-__ v_e_iD_c_a_D_D_wa. :ue ~h_e_:~na C.8 __ V_8_1 _a_a_a_U_t_o_m_o_~ .J.J 
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were carried out, air bubbles could escape from the 
graft vessels before blood supply was restored. 
Since instituting this simple preventive measure, no 
further such difficulty has been encountered. 
Diagnostic pitfalls. Until the past 2 or 3 yr, 
postoperative hepatic dysfunction was too readily 
ascribed to rejection when, in fact, biliary obstruc-
tion and/or I;holangitis were frequently responsible. 
Even in the labsence of biliary tract problems, rejec-
tion may not be responsible. Hepatitis caused by 
HBsAg, CMV, and other viruses have been ob-
served, as well as drug toxicity. At the present time, 
the development of jaundice after transplantation is 
a signal for cholangiography and usually for liver 
biopsy. The histopathologic findings in the biopsy 
tissue may not provide an unequivocal answer. 
Thus, the diagnosis of rejection must be made by ex-
clusion. 
Subsequent Experience 
In July 1976, a new series was begun, which 
was completed in December 1977. The operative, di-
agnostic, and management improvements described 
above were used. Of the 30 consecutive recipients, 
13 are alive after 1-2.5 yr (Table 1). A fourteenth re-
cipient, a child, died at 23 mo of systemic chicken 
pox and bacterial infection. A fifteenth patient died 
after 16.5 mo, with chronic rejection and portal vein 
thrombosis. Thus. the 1-yr survival in this most re-
cent experience was 50"10 (Table 1). Compared with 
the first series, tKe 1-yr survival of children has es-
sentially doubled (34"10 to 62"10). as has the survival of 
the adults (20% to 41"10). 
Early Deaths in Second Series 
It is pertinent to examine the reasons for the 
15 failures within the 1st yr in the latest Colorado se-
ries (Table 2). Technical and mechanical problems 
were still common in spite of efforts to prevent 
these. Some were due to preexisting pathology. 
Thrombosed portal veins were found in two recipi-
ents at the time of transplantation. making complete 
revascularization impossible; the patients died 
within a few days of liver failure. 
There were five enteric fistulas (two small bowel. 
one colonic. one biliary. and one from the hepatic ar-
tery into the jejunum). Three of the 5 patients, in-
cluding 1 who required emergency colectomy, had 
sclerosing cholangitis and a history of ulcerative co-
litis. An additional patient received a liver homo-
graft so large that the abdominal incision could not 
be closed: he was never able to breathe. A child with 
congenital heart disease who had a satisfactory liver 
transplantation died 9 days later of heart failure and 
GASTROENTEROLOGY Vol. on. No.2 
pulmonary edema. Thus, the acceptance of high-risk 
or even hopeless candidates contributed to some of 
the failures. 
The policy of liberal use of liver biopsy has per-
mitted a better assessment of the role of rejection in 
the complex postoperative events. In our early cases, 
only the autopsy livers were available for study. and 
these organs usually had few signs of rejection. On 
this basis. we speculated that systemic over-
treatment with immunosuppressive agents. espe-
cially prednisone. might have been responsible for 
unnecessary deaths.'7.'8.32.43 
This view undoubtedly requires some revision. in 
light of our recent experience. As before. irreversible 
rejection in the recent series was not common. but 
definite rejection was frequently seen in the biopsies 
and was highly variable in degree according to the 
timing of the biopsy (see case OT 134. Table 2). Yet. 
many of the homografts at autopsy were free of re-
jection. Intensification of immunosuppression was a 
justified action to save these livers. but a lethal one if 
there were any other kind of problem. including a 
technical or mechanical one. Thus, the tendency to 
ascribe most of the high mortality after liver trans-
plantation to factors other than rejection 17.18.32.43 is 
probably not completely correct. The possibilities 
for more effective immunosuppression are discussed 
below. and it is upon such advances that the next 
major jump in survival will undoubtedly depend. 
The gradual increase in survival with increased 
experience has not been unique in Colorado. A simi-
lar improvement has occurred in the Cambridge-
King's College units. Among the 39 patients treated 
there in 1976 and 1977, 9 had lived more than 1 yr as 
of May 1978, and 6 more were alive with shorter fol-
low-ups of 1 wk to 10 mo. '8 
Deaths After One Year 
As mentioned above, 46 liver recipients have 
lived for at least 1 yr after having received ortho-
topic liver grafts in Colorado. Nineteen of these 46 
patients subsequently died (Table 3). Their total sur-
vival averaged more than 3 yr, with the range of 12.5 
mo to 6 yr. 
Seven patients each received two liver transplants 
(Table 3). When retransplantation was attempted 
because of liver failure 1 yr or more after the original 
grafting, 4 of 5 patients died within the 2 ensuing 
months from infections and from technical compli-
cations such as enteric fistulas. However, 1 patient, 
whose first graft failed after 23 mo, lived for another 
13 mo on a second liver. The record was only 
slightly more encouraging with early retransplanta-
tion. Two children whose primary grafts failed after 
5 and 9 wk. respectively, lived for 11 and 15 mo after 
> 
--
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Figure 4. Transhepatic cholangiogram 14 mo postoperative in a 12-yr-old patient (OT 126) who received an orthotopic liver transplant 
15 mo previously. Biliary reconstruction initially was with cholecystojejunostomy (see Figure 18). Twelve months post-
operatively, this was converted to choledochojejunostomy (see Figure lC). The cholecochojejunal anastomosis is marked with 
an arrow. 1 = jejunum. 
retransplantation (OT 16 and 98, Table 3). Chronic 
rejection, with its characteristic occlusive arterial le-
sions and parenchymal fibrosis, was diagnosed in 
five of the seven primary grafts that were replaced 
with second grafts (Table 3). 
With or without retransplantation, the causes of 
death were invariably multiple, and in almost all 
cases infection supervened terminally. However, 
one or two most important underlying factors were 
usually identifiable (Table 3). Liver failure was the 
most common (11 examples), usually caused by 
chronic rejection (Table 3). Four patients, however, 
died from complications of treated or untreated bili-
ary obstruction, and in 2 more, hepatitis was respon-
sible (Table 3). 
Overwhelming systemic infections as an isolated 
complication (two examples) and recurrent cancer 
(two examples) were responsible for other deaths af-
ter 1 yr. 
Generally speaking. the patients who died after 12 
mo were already in trouble at the 1-yr mark. Only 7 
were thought to be satisfactory or excellent at that 
time. The other 12 were receiving too much predni-
sone to have a good long-term outlook. Doses in indi-
vidual cases are given in Table 3. In the entire group 
of 19, the prednisone doses at 1 yr averaged 0.74 mg/ 
kg/day. Eleven of the 19 patients were jaundiced at 1 
yr; their bilirubin values ranged from 2 to 40 mg% 
(Table 3). The average bilirubin in all 19 patients 
was 9.1 mg%. 
Late mortality has also been encountered in the 
Cambridge-King's College experience.,e By May 
1978, CaIne and Williams had followed 12 patients 
for at least 1 yr, of whom 6 subsequently died. The 
latest of the deaths was at 5.3 yr and was caused by 
biliary obstruction and cholangitis. 
The Quality of Life 
Patients who died after one year. The gener-
ally poor course of the 19 patients who died after 1 
yr was reflected in the length of their hospital-
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ization.M As a group, they were institutionalized an 
average of 55% of the time during the 1st yr, and dur-
ing their subsequent survival they spent 58% of their 
time in the hokpital. 
Thus, it was not surprising that good rehabilita-
tion was not obtained. Almost all of the eight infants 
in this failed group created severe domiciliary prob-
lems for their parents. Of 11 preadolescents, teen-
agers, and adults, only six returned to school or 
work for significant periods. 
The best rehabilitation was in 4 patients who had 
an excellent clinical result at 1 yr (aT 19, 27, 36, and 
78; Table 3). One adult died after 25 rna of recur-
rence of the duct cell carcinoma for which he Was 
treated originally (aT 78). A 4-yr-old child was well 
for 3 yr but sustained crippling liver and renal dam-
age after a hemophilus infection and died several 
weeks later (aT 19); the homograft had chronic re-
jection. Another patient died from biliary tract com-
plications and chronic rejection 6 yr after trans-
plantation (aT 27). The fourth recipient (aT 28) 
eventually had recurrence of chronic aggressive 
hepatitis, HBsAg positive, which had destroyed the 
native liver.'" 
Patients still alive. In contrast to those who 
died after 1 yr, the 27 patients who are still alive 
were doing well at 12 mo. At the l-yr mark, only 2 
were jaundiced, and the average bilirubin in the en-
tire group was 1.4 ± 2.3 (S.D.) mg%. The prednisone 
dose averaged 0.59 ± 0.4 mg/kg/day. 
Most of these ,J1atients returned to society. Al-
though they spent an average of 37% of the 1st yr af-
ter transplantation in the hospital, thereafter they 
have been hospitalized an average of only 4% of the 
time. Thus, they became free to pursue normal inter-
ests and achieved a high degree of rehabilitation. All 
GASTROENTEROLOGY Vol. 77, No.2 
the adults returned to work. The adolescents, teen-
agers, and children have been in public or special 
schools. Many of the children who were infants at 
the time of transplantation eventually bilcame stu-
dents, reflecting the fact that in this group of 27 pres-
ently alive. there have been more than a doze!! 4-yr 
survivors and seven who have been living for ihore 
than 5 yr. 
Children with good clinical results have tended to 
remain small as a result of long-term steroid ther-
apy, but they have achieved steady growth. One of 
our adult female recipients who is 4 yr post trans-
plantation had a normal baby more than a 1.5 yr ago. 
Changing Views About Recipient Selection 
The indications and appropriate conditions 
for liver transplantation have evolved empirically at 
our center and in England, and have undergone ma-
jor changes in the last 15 yr according to expanding 
experience. The diseases for which liver replace-
ment has been carried out in Colorado are listed in 
Table 4, along with the survivals at 1 yr and beyond. 
Hepatic malignancy. When the operation 
was first performed on a human in 1963, it was 
thought that otherwise unresectable primary hepatic 
malignancy would be a prime indication. Con-
sequently, 12 of the first 26 recipients had primary 
hepatic malignancies. In subsequent cases (aT 27-
141), only 7 more patients of this kind were repre-
sented, for a total of 19. Ten of the 19 recipients died 
within the first 3 rna but not because of tumor; 2 of 
the 10 had metastases at autopsy. Of the 9 who lived 
longer than 3 rna, all but 1 eventually developed me-
tastases, including 4 with hepatomas, 2 with duct 
cell carcinomas, and 1 each with heman-
Table 4. Indications for Orthotopic Liver Transplantation at the University of Colorado 
Diagnosis 
Biliary atresia 
Chronic aggressive hepatitis 
Primary liver malignancy 
Alcoholic cirrhosis 
Alpha)-antitrypsin deficiency 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Wilson's disease 
Massive hepatic necrosis (B virus) 
Congenital biliary cirrhosisb 
Budd-Chiari syndrome 
Congenital tyrosinemia 
Type IV glycogen storage disease 
Total 
Number of cases 
48 
360 
19 
15 
5 
5 
4 
2 
2 
1 
1 
1 
1 
141 
o Two had neonatal hepatitis and were treated at ages 7.5 and 30 yr. 
b With congenital deafness. 
Lived> 1 yr 
16 
12 
5 
4 
3 
1 
o 
1 
2 
o 
1 
1 
o 
o 
46 
Presently alive (1-9 yr) 
8 
7 
2 
4 
2 
1 
1 
1 
1 
27 
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gioendothelial sarcoma and sclerosing cholangio-
carcinoma. The only exception was a woman who 
died of neurologic complications 5 mo after liver 
transplantation for hepatoma. Thus, the recurrence 
rate was 89% in patients living beyond 3 mo. 
Five of the patients who survived 3 mo lived for 
more than 1 yr, and some of them achieved worth-
while palliation. Two patients with hepatomas lived 
for 13 and 14 mo; metastases were present- in both 
but were primarily responsible for the death of only 
one. One patient with duct cell carcinoma died of 
metastases after 25 mo, and another one is alive 4.25 
yr postoperatively, but with known recurrence. A 
5th patient is still alive more than 2 yr post-
operatively but she has metastases from a sclerosing 
cholangiocarcinoma. 
The only patient cured of a hepatic malignancy by 
us was a child. not included in the aforementioned 
19 cases. who had a small incidental hepatoma in 
her liver at the time of transplantation for biliary 
atresia. This girl is now 9 yr postoperative. Another 
child whose alphat-antitrypsin deficient liver con-
tained an incidental small hepatoblastoma seems tu-
mor free at 1 yr. 
A high incidence of recurrence has also been re-
ported from Cambridge-King's College (70% in pa-
tients with extended survival). The English workers' 
view of liver replacement for hepatic malignancy is, 
however. more optimistic than ours. particularly 
with respect to hepatomas.t8-tll Like us. they have 
uniformly had recurrence of duct cell carcinomas. 
However. the yield from liver replacement for pri-
mary hepatic malignancy is apt to be limited. The 
argument has even been advanced that residual tu-
mor growth may actually be accelerated by the im-
munosuppression necessary to control rejection/ 
Non-neoplastic disease. We have come to the 
general position that anyone with chronic non-neo-
plastic liver disease. who is less than 45 or 50 yr old 
(exceptional older patients may be acceptable), and 
who has a hopeless prognosis is a potential can-
didate for liver transplantation. Our experience with 
infants and children has actually been better than 
that with adults (Table 1). Thus, we consider the pe-
diatric recipient to be favored. This attitude is re-
nected in the high numbers of patients treated for 
biliary atresia (Table 3). Biliary atresia was the 
single most common indication for liver replacement 
at Colorado. The Cambridge-King's College team 
does not perform the procedure on pediatric recipi-
ents, partly because of the concern with the growth 
retardation with long-term high-dose steroid therapy 
and partly because of their difficulty in finding pedi-
atric donors.1I1 
There has been a high proportion of cirrhotics in 
our experience. Among the 68 adults treated by us 
from 1963 through 1977, 51 had Laennec's cirrhosis 
or chronic aggressive hepatitis (Table 3). It is in such 
patients that the technical challenges mentioned ear-
lier are encountered. Nevertheless, we continue to 
treat such patients, believing that this is where the 
most important future application of liver trans-
plantation lies in adults. 
For patients with chronic aggressive hepatitis, it 
would be ideal to have the patient virus free, but 
some of the patients have preexisting positive 
HBsAg tpsts. The Cambridge-King's College physi-
cians have succeeded in clearing the HBsAg marker 
postoperatively with the use of hyperimmune 
serum.t7•t8 We have not been successful in per-
manently eliminating the HBsAg marker. Several of 
our longest survivors have remained or become 
HBsAg carriers. Two have developed chronic ag-
gressive hepatitis in a modified form (OT 121, Table 
2; OT 36, Table 3). One of these cases has been re-
ported in detai1.45 Even so. the presence of the 
HBsAg is not necessarily a contraindication to trans-
plantation, although the public he.Jlth hazards of 
such carrier patients are obvious. 
In our series, a small group with inborn errors of 
metabolism have been unusually interesting because 
of the biochemical abnormalities that could be stud-
ied.- These have included Wilson's disease, al-
phat-antitrypsin deficiency. congenital tyrosinemia, 
and Type IV glycogen storage disease. The meta-
bolic derangements of all these disorders are cor-
rected for as long as the new liver functions. 
The role of tissue typing in patient selection. 
It is unlikely that shopping for well-matched livers 
will be possible in the near future. The need for 
transplantation is so pressing in appropriate can-
didates that it too often is obligatory to proceed witli 
the first available organ. Thus, almost all the 
matches in our series have been bad ones. In 100 
consecutive Colorado cases, only 2 patients received 
livers with three or four antigen matches. One of the 
recipients of a well-matched organ died of technical 
complications 62 days after operation. The other is 
well after 11 mo. 
Because of urgent needs, a number of liver trans-
plantations have been performed despite the pres-
ence of the recipients of cytotoxic antibodies that 
were anti-donor specific. We have carried out ten 
liver transplantations under these circumstances. 
There were no examples of hyperacute rejection, 
which almost invariably destroys renal homografts 
under these circumstances, and in fact, no unequivo-
cal harmful effects have been seen later (Table 5) 
compared with patients without cytotoxic anti-
bodies. Seven of the patients lived for more than 2 
mo and 5 for more than 6 mo. We»'· and CalDe and 
Williamat7•18 have concluded that the liver ia JUably 
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Table 5. Liver Transplantation into Recipients with Anti-donor Antibodies 
Number of cases Hyperacute rejection Survival> 2 mo Survival> 6 mo 
Positive cytotoxic cross-match 
Blood group incompatibility 
10 
11 
privileged in confrontations with preformed cyto-
toxic antibodies. 
Renal homografts are also hyperacutely rejected if 
there is a breach of blood group barriers. We have 
proceeded in spite of this adverse factor in 11 liver 
recipients who could not wait for blood group com-
patible organs (Table 5). The livers did not function 
well in two of the recipients. leading to attempted 
retransplantation and eventual death. The blood vio-
lations in these cases were B to 0 and B to A. The 
excised primary livers had superficial infarcts and 
focal necrosis. but histopathologically there was 
nothing to suggest damage by anti-blood group 
isoagglutinins. Thus. we will still perform trans-
plantation despite blood group incompatibility. al-
though we avoid the condition. if possible. Except in 
the two exceptional cases, the other patients did not 
behave differently than those given blood group 
compatible livers (Table 5). 
A Need for Better Immunosuppression 
The complexity of liver transplantation has 
been made clear in preceding sections, with empha-
sis on the technic)ll and management difficulties that 
may be encountered. As solutions to such problems 
are evolved. further improvements in results will de-
pend upon better means to control rejection. In the 
past, immunosuppression has been with double 
(azathioprine and prednisone) or triple drug 
(azathioprine. prednisone. and heterologous ALG) 
treatment. Cyclophosphamide can be substituted for 
azathioprine. The complications of these agents 
have already been mentioned. 
One possibility for improvement could be better 
drug treatment. A promising new agent, the fungus 
extract, Cyclosporin A,50·51 has permitted spectacular 
success after skin and/or whole organ trans-
plantation in rats. rabbits, dogs. and pigs50-54 and has 
been used in a limited clinical trial of renal homo-
transplantation at Cambridge. England. CaIne says 
that several human recipients of cadaveric kidneys 
have been treated with this drug and discharged 
from the hospital in good condition even though no 
corticosteroids were given. 
An alternative that we have been examining in 
our liver recipients is thoracic duct drainage.55 Be-
tween February and early July 1978. patients had 
thoracic duct drainage instituted at the time of liver 
transplantation (seven examples). or 2 or 3 wk later 
o 
None definite 
7 
8 
5 
6 
(two examples). Triple drug immunosuppression 
was used. It has seemed possible with this approach 
to use much less than the conventional doses of 
prednisone with adequate control of rejection. Five 
of the 9 patients have been discharged from the hos-
pital and have been followed for 6-11 mo. Four died. 
but the causes of death were unrelated to the suc-
cess of the thoracic duct fistula. Two of the patients 
died from gastrointestinal perforations and fistulas 
which resulted in overwhelming infections. In a 
third case. a 5-yr-old child with a seemingly perfect 
result died of systemic chicken pox (including 
pneumonitis and hepatitis) 72 days postoperatively. 
A 4th patient. who received a liver in violation of red 
blood cell match and whose new liver never func-
tioned well. is described above. Thoracic duct drain-
age in combination with the conventional triple drug 
therapy described above is planned for all cases in 
the immediate future. Our present policy is to estab-
lish the thoracic duct fistulas preoperatively. if cir-
cumstances permit. and to continue them for about 2 
mo. 
Auxiliary Liver Transplantation 
The alternative to hepatic replacement is to 
leave the native liver in place and to transplant an 
extra liver to an ectopic site such as splenic bed, 
right or left paravertebral gutter, or pelvis. This ap-
proach was originally conceived by Welch l and first 
tried clinically by Absolon et al. 15 The main theoreti-
cal advantage of auxiliary transplantation is that the 
recipient is not at the outset placed totally at the 
mercy of homograft function. A second possible ad-
vantage would be avoidance of the technical haz-
ards of recipient hepatectomy. 
By May 1969. nine auxiliary liver transplants had 
been performed. four at the University of Colorado 
and one each at five other institutions. These early 
cases were summarized in a book.' The longest sur-
vival was 36 days. Of the many problems encoun-
tered. not the least was difficulty in finding room for 
an extra organ in an already overcrowded abdomen. 
In addition. it had been learned from animal stud-
ies'·565' that optimum condition for the transplanted 
liver was portal venous inflow of splanchnic venous 
blood. Subsequent work56 has shown that specific 
substances in portal blood (especially insulin) can 
influence hepatic structure. function. and the capac-
ity for regeneration . 
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Since 1969, we have performed only one auxiliary 
transplantation, for the treatment of a child with 
Crigler-Najjar syndrome. The recipient died after 
the homograft vessels thrombosed. Fortner and his 
associates have maintained, however, an interest in 
auxiliary transplantation, and in September 1978, 
they summ8iized their results and those obtained 
elsewhere.59 
By that time, they had information on 43 cases, in-
cluding seven of their own. There was one unquali-
fied success, of a patient with biliary atresia who 
was alive 5.5 yr postoperatively. During the period 
after transplantation, the native liver had undergone 
striking atrophy and the original proturberance of 
the overdistended abdomen had receded. Another of 
Fortner's patients with biliary obstruction from an 
intrahepatic cancer had temporary clearing of jaun-
dice but died 8 mo later. The other 41 patients died 
in less than 2 mo from a variety of complications.5!I 
Fortner has concluded that patients with non-
neoplastic liver disease who have small livers are 
candidates for auxiliary hepatic transplantation. 
The possible attractiveness of such an option has 
been diminished by the improved results with liver 
replacement. Our view is that auxiliary trans-
plantation should be reserved for patients with 
acute hepatic disease in which the objective is tem-
porary life support during which recovery of the na-
tive liver can be obtained. The feasibility of this ap-
proach has been proved in several animal studies, 
but not yet in humans. 
Summary 
Liver transplantation in humans was first attemp-
ted more than 15 yr ago. The l-yr survival has slow-
ly improved until it has now reached about 50%. 
In our experience, 46 patients have lived for at least 
1 yr. with the longest survival being 9 yr. The high 
acute mortality in early trials was due in many cases 
to technical and management errors and to the use 
of damaged organs. With elimination of such fac-
tors. survival increased. Further improvements will 
depend upon better immunosuppression. Orthotopic 
liver transplantation (liver replacement) is the pre-
ferred operation in most cases, but placement of an 
extra liver (auxiliary transplantation) may have a 
role under special circumstances. 
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